Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

This study has been terminated.
(Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated)
Sponsor:
Information provided by (Responsible Party):
AVAX Technologies
ClinicalTrials.gov Identifier:
NCT00003715
First received: November 1, 1999
Last updated: December 2, 2015
Last verified: December 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given